A model backed by research
Our Mission
We make healing sustainable by uniting an integrated yogic approach with the wisdom of plants, people, and science. Psychedelic-supported therapy may be incorporated into a resident’s treatment when clinically appropriate, voluntarily selected, and permitted under Colorado law.
Natural medicine is one potential therapeutic tool that, if used, exists within an established residential treatment relationship—not an isolated nor recreational encounter.
A new paradigm of healing: Backed by research
Why is natural medicine one of the healing modalities at Mycelia? Clinical and neuroscience research suggests that psychedelics can temporarily increase neuroplasticity, creating an opportunity to disrupt deeply entrenched patterns associated with addiction, trauma, and depression. The research also underscores that lasting change depends not on the medicine alone, but on the therapeutic context, preparation, integration, and continued care surrounding the experience—the kind of holistic approach we’ve build at Mycelia.
The research behind psychedelic-assisted therapy
Listen
“How Psychedelics Might Open the Brain for Learning Plus Treating Addiction with Ibogaine” — Colorado Matters
In this February 2026 episode, Andrea Dukakis explores psychedelic research with Gül Dölen, including the possibility that psychedelics temporarily increase the brain’s capacity for learning and change and the emerging interest in ibogaine for addiction. The resource provides a strong bridge between neuroscience and clinical treatment, emphasizing that psychedelics may create an opportunity for change but that therapy, professional support, and continued care are essential to turning that opportunity into lasting improvement. Listen to the podcast here.
“Psilocybin Therapy for Alcohol Use Disorder and Depression with Amandine Luquiens” — Addiction Audio
This episode examines emerging research on psilocybin-assisted therapy for alcohol use disorder alongside depression, highlighting the potential for psychedelic treatment to address psychological patterns that contribute to substance use. It is especially valuable for communicating that psychedelic therapy is a structured clinical treatment involving preparation, supported dosing, and follow-up psychotherapy rather than simply providing access to a psychedelic substance. Listen to the podcast here.
“Gül Dölen: Psychedelic Science and Radical Healing” — On Being
In this March 2026 conversation, neuroscientist Gül Dölen discusses the emerging science of psychedelics, trauma, addiction, depression, neuroplasticity, and the possibility that psychedelics can reopen developmental “critical periods” in the adult brain. The conversation is particularly relevant to Mycelia because it frames psychedelics not as a standalone cure but as a potential biological window that must be shaped by therapeutic context, learning, behavior, and supportive environment. Listen to the podcast here.
“Psychedelics, Metaplasticity, Critical Periods, Social Learning, Psilocybin, LSD, MDMA, Ketamine, Ibogaine & Neuroscience”— Gül Dölen
In this March 2026 conversation, neuroscientist Gül Dölen discusses the emerging science of psychedelics, trauma, addiction, depression, neuroplasticity, and the possibility that psychedelics can reopen developmental “critical periods” in the adult brain. The conversation is particularly relevant to Mycelia because it frames psychedelics not as a standalone cure but as a potential biological window that must be shaped by therapeutic context, learning, behavior, and supportive environment. Listen to the podcast here.
“Psychedelics as Therapy” with Michael Pollen— Out Loud
The 2015 New Yorker podcast with Michael Pollan provides historical context for the modern psychedelic renaissance, showing that serious scientific investigation into psychedelics as treatments for alcoholism, depression, and other behavioral health conditions predates today's renewed interest. It also makes an important distinction between therapeutic and recreational psychedelic use, emphasizing screening, preparation, professional support, and integration as central components of clinical treatment. Listen to the podcast here.
Watch
“Veterans with PTSD Went to Mexico for a Psychedelic Retreat” — CBS News / 60 Minutes
This 60 Minutes piece follows veterans with PTSD who traveled to Mexico for psychedelic treatment, offering a human-centered look at why people with difficult-to-treat trauma are seeking psychedelic-assisted approaches. It is particularly useful for helping audiences understand psychedelic therapy through lived experience while opening a conversation about the distinction between a psychedelic experience and the larger therapeutic process surrounding it. Watch the video here.
Read
Psilocybin-Assisted Therapy for Treatment-Resistant Depression (Carhart-Harris et al., 2016)
This open-label feasibility study found that two doses of psilocybin administered with psychological support were associated with rapid reductions in depressive symptoms among people with treatment-resistant depression, supporting further investigation of psilocybin-assisted therapy.
Psilocybin-Assisted Therapy for Major Depressive Disorder (Davis et al., 2021)
In this randomized clinical trial, psilocybin-assisted therapy produced large, rapid, and sustained reductions in depressive symptoms among adults with major depressive disorder, suggesting potential efficacy that warrants further study in larger and more diverse populations.
Altering Perceptions: Psychedelic Therapy (Eck, 2022)
This Harvard Medical School overview examines the emerging evidence for psychedelic therapy, highlighting its potential in mental health treatment while emphasizing the importance of rigorous research, therapeutic support, and appropriate clinical context.
Single-Dose Psilocybin for Treatment-Resistant Depression (Carhart-Harris et al., 2022)
This phase 2 randomized trial found that a single 25-mg dose of psilocybin, administered with psychological support, significantly reduced depressive symptoms over three weeks compared with a 1-mg control dose, while also underscoring the need for further research into long-term efficacy and safety.
Long-Term Effects of Psychedelic Drugs: A Systematic Review (Aday et al., 2020)
This systematic review of 34 contemporary human studies found evidence of enduring changes across areas including depression, anxiety, wellbeing, personality, spirituality, substance use, and mindfulness, while emphasizing the need for larger, more diverse, and longer-term controlled studies.